Source: Annual Congress 2013 –New understanding of pneumococcal vaccination
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
J. Brown (London, United Kingdom). Immunity to pneumococcal disease. Annual Congress 2013 –New understanding of pneumococcal vaccination

Member's Comments

No comment yet.

Related content which might interest you: Invasive pneumococcal disease (IPN) and pneumococcal vaccination in our setting Source: International Congress 2015 – Pneumonia: determinants of clinical outcomes and potential strategies to improve its management Year: 2015 Evolutionary trend of invasive pneumococcal disease according to serotypes Source: International Congress 2016 – Community-acquired pneumonia: from prevention to treatment Year: 2016 No preventive effects of 23-valent pneumococcal polysaccharide vaccine in patients with chronic renal failure Source: International Congress 2016 – Community-acquired pneumonia: from prevention to treatment Year: 2016 The remaining challenges of pneumococcal disease in adults Source: Eur Respir Rev 2012; 21: 57-65 Year: 2012 Pneumococcal vaccination Source: Eur Respir J 2005; 26: 982-983 Year: 2005 Impact of nasopharyngeal pneumococcal colonization on dendritic cell-dependent protective immunity against invasive pneumococcal disease in mice Source: International Congress 2016 – Community-acquired pneumonia: risk classes and management issues Year: 2016 Clinical manifestations of invasive pneumococcal disease by vaccine and non-vaccine types Source: Eur Respir J 2014; 44: 1646-1657 Year: 2014 Influenza and pneumococcal vaccination Source: International Congress 2017 – State of the art session: "Respiratory infections" Year: 2017 Influenza and pneumococcal vaccination in patients with COPD Source: Virtual Congress 2020 – Pharmacological management of COPD Year: 2020 Effectiveness of a 23-valent pneumococcal polysaccharide vaccine and a 13-valent pneumococcal conjugate vaccine among the elderly with chronic respiratory diseases Source: International Congress 2018 – Pneumonia: from the community to the intensive care unit Year: 2018 Clinical presentations and serotypes causing invasive pneumococcal disease in adults vaccinated with the 23-valent polysaccharide pneumococcal vaccine (PPV23) in Spain. The ODIN study (2010-2013) Source: International Congress 2014 – The epidemiology of respiratory infections and lung cancer Year: 2014 Effects of pneumococcal vaccine in patients with chronic respiratory disease Source: Annual Congress 2007 - Different aspects of COPD exacerbations Year: 2007 Effects of pneumococcal vaccine in patients with chronic respiratory disease Source: Eur Respir Rev 2008; 17: 43-45 Year: 2008 Impact of introducing the 10-valent pneumococcal conjugate vaccine on childhood hospitalizations for bacterial pneumonia in Brazil Source: Annual Congress 2013 –Paediatric respiratory epidemiology: bronchiolitis and asthma Year: 2013 Risk factors for respiratory failure in pneumococcal pneumonia: the importance of pneumococcal serotypes Source: Eur Respir J 2014; 43: 545-553 Year: 2013 Chronic pulmonary diseases and the epidemiology of invasive pneumococcal infection Source: Annual Congress 2012 - Epidemiology: risk factors and prognosis in respiratory infections Year: 2012 Pneumococcal and influenza vaccination Source: Eur Respir Monogr 2014; 63: 266-284 Year: 2014 Aetiology of paediatric pneumonia after the introduction of pneumococcal conjugate vaccine Source: Eur Respir J 2013; 42: 1595-1603 Year: 2013 Impact of pneumococcal vaccination in children in the distribution of serotypes in bacteriemic pneumococcal pneumonia in adults Source: International Congress 2017 – Discussion of vaccines, biomarkers and risk factors analysis   Year: 2017